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Introduction
The β3-adrenergic receptor (β3-AR) has long been a therapeutic 
target to combat obesity and metabolic disease. Since the β3-AR 
is present in adipose tissue, but not in most other tissues, an 
agonist would activate thermogenesis in adipose tissue, stimu-
lating lipid oxidation and glucose consumption to produce heat 
(1, 2) without causing cardiovascular side effects. Much initial 
work has been performed in rodents, which maintain brown 
adipose tissue (BAT) throughout adulthood to defend against 
cold; indeed, treatment of rodents with β3-AR agonists acti-
vates BAT, resulting in increased energy expenditure, weight 
loss, and improved glucose and lipid metabolism (3–5). In addi-
tion to stimulating white adipose tissue (WAT) lipolysis, it is 
now recognized that β3-AR activation (or cold exposure) induc-
es the formation of brown adipocytes in subcutaneous WAT (SC 
WAT) (6), which are now called beige adipocytes (7). Recent 
studies using tissue transplantation or genetic approaches 
have demonstrated that beige adipose tissue is associated with 
improved glucose and lipid homeostasis (8–12).
BAT is highly specialized and functions to generate heat in 
response to activation of the sympathetic nervous system through 
nonshivering thermogenesis (13). The adipocytes in BAT have 
higher levels of mitochondria than do those in WAT, and these 
mitochondria have high levels of uncoupling protein 1 (UCP1). 
Activation of the sympathetic nervous system stimulates lipoly-
BACKGROUND. Beige adipose tissue is associated with improved glucose homeostasis in mice. Adipose tissue contains β3-
adrenergic receptors (β3-ARs), and this study was intended to determine whether the treatment of obese, insulin-resistant 
humans with the β3-AR agonist mirabegron, which stimulates beige adipose formation in subcutaneous white adipose tissue 
(SC WAT), would induce other beneficial changes in fat and muscle and improve metabolic homeostasis.
METHODS. Before and after β3-AR agonist treatment, oral glucose tolerance tests and euglycemic clamps were performed, 
and histochemical analysis and gene expression profiling were performed on fat and muscle biopsies. PET-CT scans quantified 
brown adipose tissue volume and activity, and we conducted in vitro studies with primary cultures of differentiated human 
adipocytes and muscle.
RESULTS. The clinical effects of mirabegron treatment included improved oral glucose tolerance (P < 0.01), reduced hemoglobin 
A1c levels (P = 0.01), and improved insulin sensitivity (P = 0.03) and β cell function (P = 0.01). In SC WAT, mirabegron treatment 
stimulated lipolysis, reduced fibrotic gene expression, and increased alternatively activated macrophages. Subjects with the 
most SC WAT beiging showed the greatest improvement in β cell function. In skeletal muscle, mirabegron reduced triglycerides, 
increased the expression of PPARγ coactivator 1 α (PGC1A) (P < 0.05), and increased type I fibers (P < 0.01). Conditioned media 
from adipocytes treated with mirabegron stimulated muscle fiber PGC1A expression in vitro (P < 0.001).
CONCLUSION. Mirabegron treatment substantially improved multiple measures of glucose homeostasis in obese, insulin-
resistant humans. Since β cells and skeletal muscle do not express β3-ARs, these data suggest that the beiging of SC WAT by 
mirabegron reduces adipose tissue dysfunction, which enhances muscle oxidative capacity and improves β cell function.
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increasing the ability of SC WAT to function as a metabolic sink 
for glucose and lipids (20) or by reducing the WAT dysfunction 
that occurs with obesity (24, 25). Substantial beiging of human 
SC WAT has been demonstrated with cancer cachexia, burns, and 
conditions with high catecholamine levels (26–29), and we have 
demonstrated the induction of UCP1 and beige adipose markers 
in SC WAT in response to cold (30). However, to our knowledge, 
no study in humans has demonstrated a link between beige fat and 
glucose or lipid metabolism.
Mirabegron is a β3-AR agonist that is FDA approved for the 
treatment of overactive bladder at a maximal dose of 50 mg /
day. In recent human studies, acute mirabegron treatment 
increased BAT activity and resting energy expenditure in lean 
humans with demonstrable baseline levels of BAT in a dose-de-
pendent manner (31–33). We treated a cohort of human subjects 
who were older, obese, and insulin resistant with mirabegron for 
12 weeks and observed that chronic mirabegron treatment stim-
ulated SC WAT beiging (30).
sis and UCP1 activation in BAT, causing energy to be converted 
to heat and consuming lipids and glucose (13). BAT is present in 
adult humans (14–17) and is associated with improved insulin 
sensitivity and glucose homeostasis (recently reviewed in ref. 
18). However, BAT diminishes with age and obesity, and there are 
questions about whether BAT activation is feasible therapeutically 
in the older, insulin-resistant human population that would be the 
logical target for drug treatment (19).
Beige adipocytes are unique, since they have a different devel-
opmental origin than brown adipocytes and are highly inducible 
by cold exposure or β-AR agonism (recently reviewed in ref. 20). 
Recent studies in mice have demonstrated that beige adipocytes 
can activate glycolytic pathways and improve glucose metabo-
lism independently of UCP1 (21) and that futile metabolic cycles 
act in addition to UCP1-mediated uncoupled respiration (21, 22). 
Beiging is also associated with reduced adipose tissue fibrosis and 
adipose dysfunction (11, 23). These findings suggest that induc-
ing beige adipose tissue may improve metabolic homeostasis by 
Figure 1. Flow chart of the study design and analysis of the research participants. Sixty-seven research subjects were assessed, and 39 were randomized 
into 3 drug treatment groups. The results for the subjects in the pioglitazone and combination therapy groups will be presented in a future publication. 
Thirteen subjects were in the mirabegron treatment group, and all completed the study.
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tolerance, and their 120-minutes glucose levels decreased from 
165 mg/dL to 120 mg/dL after treatment. Among the 13 subjects, 
9 had prediabetes according to American Diabetes Association 
criteria (i.e., having any one of the following: fasting glucose levels 
of 100–125 mg/dL, 120-minute glucose levels of 140–199 mg/dL, 
or HbA1c between 5.7% and 6.4%). Following mirabegron treat-
ment for 12 weeks, 5 of the 9 subjects were no longer prediabetic 
(i.e., did not meet any of the criteria described above). Overall, 
these subjects did not have diabetes, and the mean HbA1c level 
of the group was 5.6% ± 0.1% at baseline (Table 1). HbA1c was 
significantly lower after mirabegron treatment (Table 1; P = 0.01), 
consistent with the overall improvement in glucose tolerance.
Insulin sensitivity and pancreatic β cell function. To determine 
the underlying mechanisms for the improved glucose tolerance, 
we evaluated insulin sensitivity and pancreatic β cell function 
using the results obtained from both the OGTT and euglycemic 
clamp. Mirabegron treatment did not significantly change base-
line insulin levels (Table 1), nor did it change the homeostatic 
model assessment of insulin resistance (HOMA-IR) or the Mat-
suda index, which are measures of insulin sensitivity derived 
from the results of the OGTT (33). However, the results from 
euglycemic clamps, which are the gold standard for measuring 
insulin sensitivity (35), revealed that mirabegron treatment con-
sistently and significantly increased the glucose infusion rate 
(GIR) by approximately 12% (Figure 2B; P = 0.03). Using glu-
cose and insulin values from the OGTT, we calculated the insu-
linogenic index as an indicator of unadjusted insulin secretion. 
Using the insulin sensitivity from the clamp and the insulinogenic 
index, we then calculated insulin secretion adjusted for insulin 
sensitivity to obtain the disposition index value (36). We found 
that mirabegron treatment significantly increased both the insu-
linogenic index (Figure 2C; P = 0.02) and the disposition index 
(Figure 2D; P = 0.01), indicating improved β cell function. We 
measured insulin levels during the OGTT (Supplemental Figure 
1A) and the euglycemic clamps (Supplemental Figure 1B) and 
did not find evidence that mirabegron changed insulin clearance 
rates. Finally, although there was no significant weight loss, some 
individuals did weigh less after mirabegron treatment. We there-
fore performed analyses to determine whether the percentage of 
weight change influenced insulin sensitivity, but found no sig-
nificant relationship (P = 0.55). Together, these results indicate 
that the improvement in glucose tolerance was the result of both 
increased β cell function and improved insulin sensitivity.
Beige adipose tissue and BAT. The β3-AR has a restricted tissue 
distribution, with expression reported in white and brown adipo-
cytes and bladder smooth muscle cells. It is thus possible that the 
effects on insulin sensitivity and β cell function observed in our 
study were not direct but rather the result of SC WAT beiging or 
brown fat induction. Indeed, the activity of both beige adipose tis-
sue and BAT is associated with improved glucose homeostasis and 
postulated to involve the secretion of “batokines” to communicate 
with peripheral tissues (20). In previous studies, mirabegron was 
demonstrated to cause an acute increase in BAT activity in young, 
lean male subjects with detectable levels of BAT at baseline and 
was more effective at the higher dose of 200 mg, which is 4 times 
the FDA-approved dose (31, 32). To determine whether chron-
ic mirabegron treatment (50 mg/day) increased BAT activity in 
Here, we present the results of extensive metabolic phenotyp-
ing of an expanded cohort of obese, insulin-resistant subjects before 
and after mirabegron treatment. We found that mirabegron treat-
ment substantially improved glucose homeostasis and addressed 
many of the underlying mechanisms of insulin resistance, includ-
ing improved insulin sensitivity and secretion and improved adi-
pose tissue and skeletal muscle lipotoxicity and inflammation, yet 
had no effect on BAT in these older, obese individuals.
Results
Effect of mirabegron treatment on lipid and glucose homeostasis. A flow 
diagram showing the subject recruitment and study design is shown 
in Figure 1. We observed no significant change in body weight after 
treatment with mirabegron (Table 1). Consistent with this, mirabe-
gron treatment did not change any measure of body composition 
(Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI134892DS1) or resting 
energy expenditure (Supplemental Table 2). Mirabegron treatment 
did not significantly change plasma lipid levels, although there was 
a trend toward a reduction in total cholesterol (Table 1; P = 0.09). In 
addition, there were no reported side effects, in particular, no car-
diovascular side effects such as palpitations or rapid pulse. Blood 
pressure and heart rate did not change with treatment (Table 1), 
consistent with previous studies (34).
We assessed glucose homeostasis with an oral glucose toler-
ance test (OGTT) and measurement of hemoglobin A1c (HbA1c) 
levels. Fasting blood glucose was not affected by mirabegron 
treatment (Table 1); however, mirabegron treatment significantly 
improved overall oral glucose tolerance (P < 0.01; n = 12), as shown 
in Figure 2A. The glucose concentration 120 minutes after oral 
glucose ingestion was significantly lower after mirabegron treat-
ment (Table 1; P < 0.01). A subset of subjects had impaired glucose 




Number (Sex, male/female) 13 (2/11)
Age (yr) 54.8 ± 2.2
BMI (kg/m2) 32.4 ± 1.1
Weight (kg) 88.0 ± 2.6 87.5 ± 2.6 0.34
Systolic BP (mmHg) 127.8 ± 4.8 125.5 ± 3.5 0.42
Diastolic BP (mmHg) 79.8 ± 2.3 81.4 ± 2.6 0.61
Heart rate (beats/min) 68.7 ± 1.6 70.7 ± 1.8 0.32
Fasting glucose (mg/dL) 97.0 ± 2.8 95.8 ± 3.1 0.49
Fasting insulin (μU/mL) 13.2 ± 2.7 14.4 ± 2.3 0.4
120-minute glucose (mg/dL) 135.3 ± 7.5 109.8 ± 6.4 < 0.01
HbA1c (%) 5.6 ± 0.1 5.4 ± 0.1 0.01
TG (mg/dL) 144.0 ± 22.9 130.1 ± 18.0 0.35
Cholesterol (mg/dL) 215.7 ± 11.2 205.7 ± 11.6 0.09
HDL (mg/dL) 56.6 ± 5.1 55.9 ± 4.7 0.71
LDL (mg/dL) 132.9 ± 7.8 125.4 ± 8.6 0.15
AResearch participants were treated with mirabegron (50 mg/day) for 12 
weeks. Data indicate the mean ± SEM (n = 13). BData were analyzed by a 
paired, 2-tailed Student’s t test.
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Systemic inflammation and skeletal muscle lipotoxicity. Inflam-
mation and lipotoxicity are both implicated in the development 
of insulin resistance and reduced β cell function in the context of 
obesity in humans. We measured plasma levels of adiponectin, 
high-molecular-weight (HMW) adiponectin, TNF-α, and mono-
cyte chemoattractant protein 1 (MCP1). Plasma levels of TNF-α, 
MCP1, or total or HMW adiponectin did not change after mirabe-
gron treatment (Supplemental Table 4). We measured triglyceride 
(TG), diacylglyceride (DAG), and ceramide levels in vastus later-
alis muscle biopsies to determine whether mirabegron treatment 
reduced lipotoxicity. Mirabegron treatment caused a slight reduc-
tion in TG levels (Figure 3A; P = 0.04) but did not reduce levels of 
the lipotoxic lipids ceramide or DAG (Figure 3, B and C).
We investigated mechanisms for the reduction in muscle TG. 
PPARγ coactivator 1 α (PGC1α) is part of a transcriptional network 
that regulates muscle fiber type determination and promotes fatty 
acid oxidation, mitochondrial biogenesis, and type I fiber forma-
tion (37, 38). PGC1A mRNA expression was significantly increased 
in muscle following mirabegron treatment (Figure 3D; P < 0.05). 
Both mitochondrial transcription factor A (TFAM1) and cycloox-
ygenase IV (COX IV) were increased after mirabegron treatment 
(Figure 3, E and F; P < 0.01), consistent with the induction of 
PGC1A. In addition to PGC1A, we measured the mRNA expres-
sion of perilipin 5 (PLIN5), which is associated with increased 
insulin sensitivity. This increase is thought to be due to the ability 
of PLIN5 to promote fatty acid oxidation (39). We observed that 
older, insulin-resistant individuals, we performed cold-stimu-
lated PET-CT before and after mirabegron treatment. As shown 
in Figure 2E, mirabegron treatment did not increase BAT volume. 
Notably, 8 of the subjects had no demonstrable BAT at baseline, 
and there was no increase in BAT in these subjects following mira-
begron treatment. There was also no increase in any measure of 
glucose uptake by BAT (Supplemental Table 3).
We previously observed that mirabegron treatment signifi-
cantly induced beiging of SC WAT in 6 subjects (30) who were 
among the 13 subjects in this report. Consistent with that study, we 
found that mirabegron treatment increased protein expression of 
the beige adipose markers UCP1 (2.4-fold, P < 0.0001), transmem-
brane protein 26 (TMEM26) (4.2-fold, P < 0.001), and cell death–
inducing DFFA-like effector A (CIDEA) (2.4-fold, P < 0.01) in SC 
WAT within the entire cohort (n = 13). Since mirabegron treatment 
increased beige fat, we determined whether the change in adipose 
beiging correlated with the changes in insulin sensitivity or the dis-
position index. This analysis revealed that the change in UCP1 pro-
tein expression in SC WAT significantly correlated with the change 
in the disposition index, indicating a possible beneficial relation-
ship between beige fat and pancreatic β cell function (Figure 2F; P 
= 0.05). Although we found a relationship between the change in 
UCP1 protein expression in SC WAT and the insulinogenic index, 
this change did not reach statistical significance (r = 0.46; P = 0.12). 
The change in UCP1 protein expression in SC WAT did not signifi-
cantly correlate with the change in the GIR (P = 0.27).
Figure 2. Mirabegron treatment improves glucose homeostasis in obese, insulin-resistant subjects. Subjects were treated with mirabegron (50 mg/
day) for 12 weeks. OGTTs and euglycemic clamps were performed at baseline and after treatment. (A) OGTT results and AUC for all subjects (n = 12). Data 
indicate the mean ± SEM. OGTT data were analyzed by a 2-way, repeated-measures ANOVA (***P < 0.001 and ****P < 0.0001); AUC data were analyzed 
by a paired, 2-tailed Student’s t test (**P < 0.01). (B) Euglycemic clamping was performed at an insulin infusion rate of 1.0 mU/kg/min, and the GIR was 
determined before and after treatment. Data indicate the mean ± SEM (n = 13) and were analyzed by a paired, 2-tailed Student’s t test (*P < 0.05). (C) 
The insulinogenic index was determined from the results of the oral glucose tolerance test. Data indicate the mean ± SEM (n = 12) and were analyzed by a 
paired, 2-tailed Student’s t test (*P < 0.05). (D) The disposition index is the product of (C) insulin sensitivity and (D) the insulinogenic index. Data indicate 
the mean ± SEM (n = 12). **P < 0.01, by paired, 2-tailed Student’s t test. (E) BAT volume was quantified by PET-CT scans before and after treatment. Eight 
subjects had no BAT at baseline, and BAT did not increase after treatment of these subjects. (F) The change in SC WAT beiging was calculated as the 
difference in UCP1 protein expression before and after treatment. The change in the disposition index (D) and the change in UCP1 in SC WAT were analyzed 
by regression analysis. The Spearman’s correlation coefficient and P value are indicated in F.
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changes in skeletal muscle induced by mirabegron treatment are 
probably caused by an indirect mechanism that is possibly relat-
ed to SC WAT beiging. To test this concept in vitro, we prepared 
conditioned medium (CM) from untreated adipocytes and from 
adipocytes treated with mirabegron for 16 hours. We then treated 
differentiated human myotubes with mirabegron, CM from differ-
entiated human adipocytes, or CM from adipocytes treated with 
mirabegron for 16 hours. We found that CM from untreated adipo-
cytes did not induce PGC1A mRNA expression in myotubes; how-
ever, myotubes that were incubated with CM from adipocytes that 
were treated with mirabegron had significantly increased levels of 
PGC1A expression (Figure 4; P < 0.001), suggesting that mirabe-
gron treatment caused adipocytes to release a factor that induced 
PGC1A mRNA expression in muscle. As an additional control to 
account for any effect of mirabegron on myotubes, we harvested 
CM from adipocytes and then added mirabegron to it and treat-
PLIN5 was upregulated with mirabegron treatment (Figure 3G; P < 
0.01). A possible explanation for these changes in gene expression 
is that mirabegron treatment changed the fiber type composition 
of skeletal muscle; therefore, we quantified type I, type IIa, type 
IIx, and type IIa /IIx fibers. As shown in Figure 3, H–L, the per-
centage of type I fibers significantly increased (P < 0.01), the per-
centage of type IIa fibers significantly decreased (P < 0.05), and 
neither type IIx nor type IIa/IIx fibers changed following mirabe-
gron treatment.
Real-time reverse transcription PCR (RT-PCR) revealed no 
mRNA expression of the β3-AR in muscle; as expected, we were 
able to detect mRNA expression of the β2-AR (data not shown). 
Activation of the β2-AR causes skeletal muscle hypertrophy (40); 
however, we did not detect an increase in the size of the muscle 
fibers (data not shown), suggesting that mirabegron did not cause 
activation of β2-ARs at the dose used in this study. Thus, these 
Figure 3. Mirabegron treatment reduces skeletal muscle TGs, but not toxic lipids, and promotes fiber-type switching to type I fibers. Lipids were 
extracted from skeletal muscle obtained from vastus lateralis biopsies and the levels of the indicated lipids were measured as described in Methods.  
The levels of (A) TG, (B) DAG, and (C) ceramide before and after mirabegron treatment were determined. (D–G) mRNA expression of genes in muscle was 
determined by real-time RT-PCR. (H) Representative images of muscle stained for MyHC I, MyHC IIa, and MyHC IIx before and after mirabegron treatment. 
Scale bars: 50 μm. (I–L) Quantification of type I, type IIa, and type IIx fibers. Data are expressed as the percentage of total fibers and indicate the mean ± 
SEM (n = 12–13). *P < 0.05 and **P < 0.01, by paired, 2-tailed Student’s t test.
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ed myotubes with this medium. CM from adipocytes treated with 
mirabegron induced higher PGC1A expression in myotubes than 
did media in which mirabegron was added after harvesting the 
CM from adipocytes. (Figure 4; P < 0.05).
Adipose tissue remodeling. We have previously reported that 
phospho–hormone–sensitive lipase (HSL) is increased after mira-
begron treatment (30), suggesting that mirabegron stimulates 
cAMP signaling in adipocytes. To determine whether mirabegron 
treatment stimulates lipolysis, we measured nonesterified fatty 
acids (NEFAs) and glycerol in the CM from adipose explants from 
subjects before and after treatment. We found that glycerol was sig-
nificantly higher in the medium of adipose tissue after mirabegron 
treatment (Figure 5A; P < 0.01) and that plasma NEFA levels were 
higher after mirabegron treatment (Figure 5B; P < 0.05). Elevated 
plasma NEFA levels are thought to contribute to ectopic lipid accu-
mulation and inhibition of insulin receptor signaling in the liver and 
skeletal muscle. Acute exposure of β cells to NEFAs stimulates insu-
lin secretion, but chronic exposure causes lipotoxicity and inhibits 
insulin secretion (41–43). As described above, ceramide and DAG 
levels in skeletal muscle were not elevated, despite the increase in 
plasma NEFAs. This raises the interesting possibility that β3-AR 
stimulation of beiging induces compensatory mechanisms, such as 
the fiber-type switching to the more oxidative type I muscle fibers 
described above, allowing for improved peripheral tissue function 
even in the presence of increased plasma NEFA levels.
To gain further insight into the effects of mirabegron on adi-
pose tissue, we analyzed SC WAT gene expression before and after 
treatment using the NanoString nCounter Multiplex system. The 
panel of 160 genes consisted of adipokines, cytokines, immune 
cell markers, and genes involved in adipocyte function, angiogene-
sis, and fibrosis (Supplemental Table 5). Fatty acid–binding protein 
4 (FABP4) mRNA expression was significantly induced following 
mirabegron treatment (Table 2; P < 0.01). FABP4, a lipid chaperone, 
is regulated by fatty acids (44) and is probably induced by mirabe-
gron treatment in response to increased lipolysis. Collagen 6 and 
elastin as well as metalloproteinases and tissue inhibitors of metal-
loproteinases (TIMPs) were significantly changed by mirabegron 
treatment, and most of these were lower after treatment (Table 2), 
suggesting a reduction in extracellular matrix (ECM) remodeling. 
The mRNA expression levels of 2 genes encoding secreted proteins 
with known effects on insulin resistance were changed: fibroblast 
growth factor 21 (FGF21), which has overall beneficial effects on 
metabolic homeostasis, was induced by mirabegron treatment, and 
resistin, which is associated with insulin resistance, was suppressed 
by mirabegron treatment. Retinol-binding protein 4 (RBP4) mRNA 
expression was elevated; RBP4 is a secreted protein that is postulat-
ed to promote local adipose tissue inflammation; however, we did 
not find increased inflammatory gene expression. Also, mirabegron 
treatment did not affect the expression of any of the β-ARs (Sup-
plemental Figure 2). Overall, mirabegron treatment yielded many 
changes in SC WAT gene expression that indicated a shift toward 
an improvement in adipose tissue function. Finally, we found that 
mirabegron did not induce changes in the plasma levels of resistin, 
FGF21, adipsin, or leptin proteins (Supplemental Table 4).
To assess adipose tissue inflammation, we measured adipose 
tissue macrophage polarization in response to mirabegron. The 
numbers of CD163+CD68+ macrophages were increased in SC 
Figure 4. CM isolated from adipocytes treated with mirabegron induces 
PGC1α expression in human myotubes in vitro. Differentiated human 
adipocytes, with or without 100 nM mirabegron treatment for 16 hours, 
and the CM was isolated as described in Methods. An additional control 
was made by adding mirabegron to the CM after the CM was isolated from 
the adipocytes. The human myotubes were then incubated with 0.025% 
DMSO (Control), mirabegron (25 nM), adipocyte CM (25%), mirabe-
gron-treated adipocyte CM (25%), or adipocyte CM plus mirabegron (25%). 
The final concentration of mirabegron was 25 nM. Data indicate the mean 
± SEM (n = 3). *P < 0.05 and ***P < 0.001, by 1-way ANOVA with Tukey’s 
multiple comparisons test.
Table 2. Changes in SC WAT gene expression caused by mirabegron
Gene symbolA Function Fold change P valueB
FABP4 Fatty acid metabolism 1.22 < 0.01
RBP4 Secreted factor 1.24 < 0.01
TIMP2 ECM 0.85 < 0.01
COL6A1 ECM 0.89 0.02
Angiopoietin 3 Angiogenesis 0.81 0.03
DGAT2 Lipid metabolism 1.24 0.03
Angiopoietin 4 Angiogenesis 1.19 0.03
MMP2 ECM 0.69 0.03
PPARG2 Transcription factor 1.18 0.04
Resistin Secreted factor 0.67 0.04
FGF21 Secreted factor 1.21 0.04
CERS6 Lipid metabolism 1.11 0.04
PKCA Kinase 0.87 0.05
Elastin ECM 0.76 0.05
GM-CSF Cytokine 0.83 0.05
MMP14 ECM 0.88 0.05
AResearch participants were treated with mirabegron (50 mg/day) for 
12 weeks, and gene expression was measured at baseline and after 
treatment. Data represent mean ± SEM (n = 13). BData were analyzed by 
a paired, 2-tailed Student’s t test. Additional information is available in 
Supplemental Table 5.
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WAT after mirabegron treatment (P < 0.05), but the numbers of 
CD86+CD68+ macrophages were not changed (Figure 6, A and 
B). This result indicates a shift toward M2 macrophage polariza-
tion and suggests reduced adipose dysfunction, consistent with 
the results of the gene expression analysis. Finally, we found 
that UCP1 was often present as punctate staining in small cells 
between the large, unilocular adipocytes. UCP1 staining colocal-
ized with CD163, and UCP1+CD163+ cells significantly increased 
in SC WAT after mirabegron treatment (Figure 6, C and D; P 
< 0.001). These results suggest that UCP1 is not only present in 
beige adipocytes but is also expressed in alternatively activated 
macrophages, which may play an important role in beige adipose 
tissue in humans.
SC WAT mitochondrial bioenergetics. We previously demon-
strated that repeated cold exposure increases mitochondrial 
uncoupling in SC WAT (30). Using similar methods, we examined 
the bioenergetic profiles of purified mitochondria from SC WAT 
before and after mirabegron treatment by measuring state 3 and 
state 4 respiration, uncoupling activity, and maximal respiration. 
The bioenergetic profiles before and after treatment with mira-
begron are shown in Figure 7, A and B. To measure UCP1-driven 
uncoupling, we calculated the difference between the oxygen 
consumption rates (OCRs) obtained during the presence of oligo-
mycin and then free fatty acids (FFAs), which were subsequent-
ly added to stimulate uncoupling. Although mirabegron induced 
UCP1 protein expression, it did not increase uncoupled respira-
tion. However, respiration in the presence of oligomycin (state 4) 
was lower after mirabegron treatment (Figure 7, A and B). As part 
of our experimental protocol, we added BSA after the addition 
of FFAs to sequester the FFAs, which demonstrated the effects 
of FFAs on uncoupling. The OCR after BSA addition was lower 
than the OCR after oligomycin addition, both before (Figure 7A) 
and after treatment (Figure 7B), and this difference (Oligo – BSA) 
likely reflects stimulation of uncoupled respiration by endogenous 
FFAs or ROS, both of which are sequestered by BSA. As shown in 
Figure 7C, Oligo – BSA was significantly lower after mirabegron 
treatment (P < 0.05). The reduction in uncoupled respiration 
(Oligo – BSA) and the increase in metabolic efficiency likely reflect 
a beneficial effect of mirabegron treatment on SC WAT.
Summary and conclusions. Mirabegron treatment improved 
glucose homeostasis in obese, insulin-resistant subjects. The 
underlying mechanisms involve both increased insulin sensitivity 
and β cell function. We found that mirabegron treatment caused 
an increase in type I fibers in skeletal muscle and had numerous 
positive effects on skeletal muscle gene expression that likely 
arose from increased PGC1α expression. These changes in mus-
cle would be predicted to increase insulin sensitivity and fatty 
acid oxidation. However, we were unable to detect ADRB3 mRNA 
expression in muscle, and the β3-AR is also not expressed by β cells 
(45). Thus, the effects on both β cells and muscle are probably indi-
rect and caused by the numerous changes to SC WAT including 
beiging, adipose tissue remodeling, and reduced inflammation. 
Mirabegron did not induce BAT, and we found no evidence of 
increased uncoupled respiration or lipid oxidation, even though 
mirabegron treatment induced UCP1 protein expression in SC 
WAT. Furthermore, the beneficial physiological effects of mira-
begron treatment on glucose metabolism, insulin sensitivity, and 
β cell function occurred paradoxically in the presence of increased 
plasma NEFA levels. The increased NEFA levels did not result 
in muscle lipotoxicity, which may be due to an increase in type 
I fibers, suggesting that protective mechanisms are induced by 
mirabegron treatment. This human study supports the previous-
ly proposed concept that adipose beiging has beneficial effects on 
glucose metabolism, which can be UCP1 independent (21).
Discussion
Considerable evidence points to BAT and beige adipose tissue 
as both a metabolic sink for glucose and lipids and a source of 
“batokines” that affect peripheral tissues (20). β3-AR activation is 
currently the best-known pharmacological approach for stimulating 
brown and beige fat, and the β3-AR agonist mirabegron was demon-
strated to be effective in activating BAT and inducing beige adipose 
in humans (30–32). The current study differs from previous ones in 
several important ways. In this study, we targeted an at-risk popu-
lation: individuals with metabolic syndrome or prediabetes rather 
than lean, healthy subjects. In addition, the standard FDA-approved 
dose of mirabegron was used for 12 weeks and was very well toler-
ated, whereas previous studies used this β3 agonist only acutely and 
sometimes in doses that had cardiovascular side effects. Finally, 
this study focused on both SC WAT beiging as well as BAT, along 
with a mechanistic examination of adipose and muscle.
The main findings of this study are that mirabegron treat-
ment improved glucose metabolism in the absence of weight 
loss and that this improvement in glucose metabolism was clin-
ically significant. Indeed, a recent study suggests that in a pop-
ulation of nondiabetic subjects, changes in glucose tolerance 
or HbA1c, as observed in our study, would be expected with a 
Figure 5. Mirabegron treatment stimulates lipolysis. (A) Adipose tissue 
(0.5 g) from the SC WAT biopsy was placed in medium and kept at 37°C for 1 
hour, and the level of glycerol was determined in the adipose tissue explant 
CM before and after treatment. (B) Plasma NEFA levels were determined 
before and after treatment. Data indicate the mean ± SEM (n = 13). **P < 
0.01 and ***P < 0.001, by paired, 2-tailed Student’s t test.
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and some were preselected as having demonstrable BAT. Older, 
obese humans often have little or no demonstrable BAT (16, 52). 
One study did demonstrate detectable BAT in obese men but used 
a prolonged cold exposure protocol (53). In this study, the inability 
of mirabegron treatment to recruit BAT is probably because of the 
low levels of BAT at baseline in this older, obese cohort.
Although adults with obesity have little BAT, there is consider-
able WAT, and both cold and mirabegron stimulate SC WAT beig-
ing, with increases in UCP1, CIDEA, and TMEM26 (30). In spite 
of a clear mirabegron-induced increase in UCP1 protein expres-
sion in SC WAT, we did not detect an increase in uncoupled res-
piration in purified mitochondria from WAT. In a previous study 
using the same methods, cold exposure of lean subjects increased 
uncoupled respiration in mitochondria isolated from SC WAT with 
a similar level of induction of UCP1 (30). The reasons for the fail-
ure of mirabegron to induce uncoupling activity are unclear, but it 
could be that mirabegron induced CIDEA, an inhibitor of UCP1 
activity (54). Mirabegron may have affected ROS levels, which are 
necessary to activate UCP1 (55).
Although there was no increase in uncoupled respiration with 
mirabegron, the increase in lipolysis observed in this study and the 
previously reported increase in HSL phosphorylation on a serine 
residue that is a protein kinase A site (serine 660) (30) suggest that 
mirabegron stimulated cAMP signaling in SC WAT. Furthermore, 
mirabegron treatment caused numerous changes in the expres-
sion of genes, most of which are predicted to reduce adipose tissue 
dysfunction. To gain a mechanistic understanding of the improve-
ment in glucose metabolism, we attempted to identify changes in 
plasma levels of adipokines and in proteins whose adipose gene 
expression was altered by mirabegron. For instance, FGF21 has 
many favorable metabolic effects and was upregulated in SC WAT 
after mirabegron treatment (56). Resistin was initially discovered 
weight loss of more than 16% (46). Finally, our observations 
that mirabegron treatment had beneficial effects (an increase 
in both insulin sensitivity and β cell function) on cell types that 
do not express the β3-AR indicate that SC WAT beiging affects 
the function of peripheral tissues. Indeed, we identified a signif-
icant correlation between the change in SC WAT UCP1 expres-
sion and the change in the disposition index, but not with the 
change in insulin sensitivity. Furthermore, we were not able to 
identify plasma adipokines that changed in response to mira-
begron treatment. This finding suggests that mirabegron treat-
ment may have had only a modest effect on adipose tissue or 
caused other tissues that express the β3-AR to influence periph-
eral tissues involved in glucose homeostasis. Indeed, a recent 
study involving lean humans demonstrated that mirabegron 
influences bile acid metabolism (32).
The effects of mirabegron on metabolism have recently been 
studied in mice, and there are notable differences between those 
studies (5, 47) and this one in humans. For instance, treatment 
of ApoE–/– mice with mirabegron increased total and LDL choles-
terol and promoted atherosclerosis (47), but the current study in 
humans found a trend toward decreased cholesterol and no evi-
dence for an increase in LDL. In another study in mice, mirabe-
gron improved insulin sensitivity and glucose tolerance but also 
induced weight loss and significantly increased BAT activity (5). 
In this human study, mirabegron treatment clearly affected the 
function of peripheral tissues involved in glucose homeostasis, but 
there was no weight loss, and BAT activation was not a factor; the 
presence of BAT in mice, but not obese humans, likely accounts 
for the different responses. Other studies have demonstrated that 
both cold and mirabegron are capable of inducing BAT recruitment 
in humans (31, 32, 48–51). However, the participants in those stud-
ies were usually lean and younger than the subjects in this study, 
Figure 6. Mirabegron treatment increases alternatively activated macrophages in SC WAT. To characterize macrophage polarization, adipose tissue sections were 
doubly stained for (A) CD86 and CD68 (M1) and (B) CD163 and CD68 (M2). (C) UCP1 was present in CD163+ cells in SC WAT. Yellow arrows point to UCP1+CD163+DAPI+ 
cells (scale bar: 50 μm). (D) UCP1+CD163+ cells were quantified in SC WAT before and after mirabegron treatment. Data indicate the mean ± SEM (n = 13). *P < 0.05 
and ***P < 0.001, by paired, 2-tailed Student’s t test.
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change in plasma NEFA levels, suggesting a relationship between 
the effect of mirabegron on SC WAT and β cell function. It is pos-
sible that this effect is mediated directly by increased NEFAs. It 
will be important to determine whether this effect persists under 
longer-term mirabegron treatment. Although NEFAs stimulate β 
cell insulin secretion acutely, the compensatory mechanisms of β 
cells during chronic exposure to increased NEFAs are detrimental 
to insulin secretion (41–43). Another possibility is that stimulation 
of beige adipose results in the release of additional factors that 
protect β cell function.
A leading hypothesis for the development of adipose dysfunc-
tion in obesity is adipocyte expansion against a rigid ECM, leading 
to adipocyte necrosis and macrophage recruitment (24, 25, 67). 
Mirabegron treatment resulted in reduced mRNA expression of 
collagen VI and several genes involved in adipose tissue remodel-
ing. Although mirabegron treatment induced lipolysis, we did not 
observe any change in adipocyte size (data not shown). This sug-
gests that the changes in ECM gene expression may be due to the 
induction of beiging, which is linked to reduced fibrosis and a less 
rigid ECM (11, 23). In addition to the changes in ECM genes, the 
number of alternatively activated macrophages (CD163+CD68+) 
increased in SC WAT after mirabegron treatment, suggesting an 
environment that is less inflammatory and more reparative. Mac-
rophages have been reported to be recruited into adipose tissue in 
response to increased lipolysis to buffer FFAs (68). We observed 
that the CD163+CD68+ macrophages recruited into SC WAT 
expressed UCP1. Although uncoupling activity in the adipose tis-
sue did not increase overall, it is possible that UCP1 was active in 
these macrophages as a mechanism of oxidizing lipids. UCP1 was 
also expressed in CD206+ macrophages, which increased after 
mirabegron treatment but did not reach statistical significance 
(data not shown; P = 0.12). The identification of UCP1 in adipose 
tissue macrophages (Figure 6C) partly explains the punctate 
nature of UCP1 staining that we observed in human WAT.
Limitations of the study. This study was designed to be a proof 
of concept, since, to our knowledge, β3-AR agonists have not been 
studied in obese humans, and we sought to comprehensively 
characterize the response to mirabegron using both basic science 
and clinical techniques. Furthermore, this study was not placebo 
controlled, and the majority of the subjects were female. A ran-
domized, blinded, placebo-controlled study with a larger number 
to be a factor secreted by adipocytes that causes insulin resis-
tance in mice (57). Studies of resistin in humans initially yielded 
conflicting results; however, 2 large studies identified resistin as a 
risk factor for the development of diabetes (58, 59). We were not 
able to identify changes in the plasma levels of FGF21, resistin, 
adiponectin, leptin, or adipsin. Overall, our findings suggest that 
mirabegron treatment affected many different pathways that have 
an impact on adipose tissue function, and it will be important to 
identify mechanisms linking changes in SC WAT to improved glu-
cose homeostasis in future studies.
One of the most interesting findings from this study was the 
change in skeletal muscle fiber types. The switch in muscle fiber 
type induced by mirabegron treatment is rather remarkable, since 
muscle fiber type is relatively resistant to a transition from type II 
to type I, even with significant interventions such as exercise and 
weight loss (60, 61). The β2-AR is expressed in muscle, and admin-
istration of β2-AR agonists causes hypertrophy as well as a shift 
from type I to type II fibers (62, 63). We did not detect an increase 
in fiber size or type I to type II switching, indicating that mirabe-
gron did not activate β2-ARs, consistent with the lack of cardio-
vascular side effects. Mirabegron increased PGC1A mRNA levels 
as well as the expression of genes regulated by PGC1α. PGC1α 
promotes type I fiber induction in mice (38), and the increase in 
PGC1A after mirabegron treatment is thus likely important for a 
number of changes including observations that lipotoxicity was 
not increased despite increased plasma NEFAs and that insulin 
sensitivity was increased. It will therefore be important to identi-
fy the mechanism for PGC1A induction by mirabegron treatment 
and to consider that beige adipose may be the source of the factor.
β Cell function was increased by mirabegron treatment. A 
recent study in mice demonstrated an acute effect of β3-AR ago-
nism on insulin secretion, and this effect was entirely dependent 
on adipose tissue lipolysis, since it was completely blocked in mice 
with adipose tissue triglyceride lipase (ATGL) deficiency (45). This 
observation suggests that the β3-AR is not expressed on pancreatic 
β cells in rodents and illustrates a communication between adi-
pose tissue and β cells. In addition to NEFAs, adiponectin, leptin, 
and adipsin are proteins secreted from adipose tissue that have an 
impact on β cells (64–66). The results of our study indicate that the 
change in the disposition index, a measure of β cell function, cor-
related with both the change in SC WAT UCP1 expression and the 
Figure 7. Mirabegron treatment reduces state 4 respiration but does not increase uncoupled respiration in purified mitochondria isolated from SC 
WAT. Mitochondria were purified and the bioenergetics analyzed using an Oxytherm before and after mirabegron treatment as described in Methods. This 
involved the sequential addition of adenosine diphosphate (ADP), oligomycin (Oligo), FFA (60 μM linoleic acid), fatty acid–free BSA, and trifluoromethoxy 
carbonylcyanide phenylhydrazone (FCCP) (10 μm). (A and B) OCRs before and after treatment are shown. (C) The difference between oligomycin and BSA 
was calculated before and after treatment. Data indicate the mean ± SEM (n = 12). *P = 0.05, by Wilcoxon matched-pairs, signed-rank test.
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usual diet and level of activity. After completing the baseline studies 
(OGTT, euglycemic clamp, fat and muscle biopsies, and PET-CT), the 
participants were treated with mirabegron (50 mg/day) for 12 weeks, 
after which the initial studies were repeated. The Clinicaltrials.gov 
identifier is NCT02919176.
Biopsies. An incisional biopsy of adipose tissue from the abdomen 
was obtained as described previously (69). Briefly, approximately 4 
grams of tissue was removed from the abdomen, most of which was 
used for the preparation of mitochondria for mitochondrial bioener-
getics analysis (30). The remainder was either frozen at –80°C or used 
for immunohistochemical analyses. A muscle biopsy from the vastus 
lateralis was also obtained using a Bergstrom needle as described pre-
viously (70). Briefly, approximately 100 mg of each biopsy was mount-
ed with fibers perpendicular to a cork using tragacanth gum; this was 
snap-frozen in liquid nitrogen–cooled isopentane and then stored at 
–80°C until sectioning.
Euglycemic clamp. Peripheral insulin sensitivity was measured 
using a euglycemic clamp, as described previously (71). The subjects 
arrived in the fasted state, IVs were inserted, and euglycemia was 
maintained through the variable infusion of 20% glucose and frequent 
blood glucose measurement during an insulin infusion of 1.0 mU/kg/
min. A steady state was generally attained at 2 hours, and the glucose 
infusion rate was determined during the final 30 minutes.
Assessment of BAT. Cold-stimulated PET-CT for the measurement 
of BAT was performed as described previously (31, 72). After an over-
night fast, the subjects were brought to the PET-CT suite 120 minutes 
before the scan and outfitted with a cooling vest that circulated water 
at 14°C. Sixty minutes before the scan, 440 MBq 18F-FDG was injected 
intravenously. Images were acquired using a Discovery LS Multide-
tector Helical PET-CT Scanner (GE Medical Systems). PET data were 
acquired from the eyes to the thighs, and both PET and CT images 
were reconstructed as axial sections at 4.25-mm spacing and then 
reformatted by the viewer software. BAT mass and activity were quan-
tified using the PET-CT Viewer shareware, and BAT in each axial slice 
was classified on a pixel-by-pixel basis when CT was in the range of 
–250 to –10 Hounsfield units and when the maximal standard uptake 
value (SUVmax) was 2.0 or higher in the cervical, supraclavicular, and 
anterior thoracic depots from C3 to T7. Areas of 18F-FDG uptake on 
PET colocalizing with regions of fat identified on CT were quantified 
by their average SUV (SUVavg), and detectable BAT volume was cal-
culated as the sum of pixels meeting this classification criteria multi-
plied by the pixel volume (64.8 mm3).
IHC on adipose tissue and muscle. IHC and quantification of 
UCP1, TMEM26, and CIDEA expression in SC WAT were performed 
as described previously (30). We performed immunohistochem-
ical analyses of macrophages (CD163+CD68+, CD206+CD68+, or 
CD86+CD68+) on 5-μm formalin-fixed, paraffin-embedded SC WAT 
sections. Tissue was deparaffinized and blocked with hydrogen per-
oxide, rinsed, and then blocked first with a Streptavidin/Biotin Block-
ing Kit (SP-2002, Vector Laboratories) followed by 2.5% horse serum. 
M1 macrophages were identified by costaining with rabbit anti-CD86 
(ab53004, Abcam) and mouse anti-CD68 (ab955, Abcam) antibod-
ies; M2 macrophages were identified by costaining with rabbit anti-
CD163 (ab182422, Abcam) and anti-CD68 antibodies. The primary 
antibodies were incubated individually overnight in 1% horse serum. 
The number of CD163 macrophages that costained with UCP1 was 
determined using mouse anti-CD163 (HM2157, Hycult Biotech) and 
of participants and males will be necessary to determine whether 
there are sex differences and to identify small changes that may 
have been missed in this study. For instance, our data indicate that 
mirabegron at the FDA-approved dose of 50 mg/day is specific 
for β3-ARs, which is based on a lack of cardiovascular side effects. 
With the sample size of this study, we cannot completely rule out 
β2-AR agonism, which could, for instance, affect β cell function 
directly or indirectly via other cells in the islet. A placebo control 
group will also be necessary to rule out a placebo effect for some 
of the small changes identified in this study, such as the small but 
consistent increase in GIR. Despite these limitations, we believe 
this study forms a strong basis for future studies on mirabegron, 
as described below.
Conclusions, perspectives, and future goals. β3-AR agonists were 
initially developed as antiobesity agents. Although β3-AR agonists 
induce weight loss in rodents, we did not observe weight loss in 
the subjects in this study. This could be due to the relatively low 
levels of BAT in humans, the mirabegron dose used, or the fact 
that humans will compensate for increased energy expenditure 
with increased food intake. Alternatively, it is possible that the 
50-mg/day dose was too low to induce beiging and UCP1 activa-
tion to a level that would increase energy expenditure and weight 
loss. However, even without weight loss or BAT activation, this 
relatively low dose was sufficient to improve insulin sensitivity 
and β cell function, despite the fact that NEFA levels increased. 
Higher doses of mirabegron would likely induce stronger beiging 
and increased lipid oxidation, which may reduce NEFAs; howev-
er, unwanted cardiovascular side effects may be limiting (31, 32). 
It will be important to determine whether long-term mirabegron 
treatment at the dose used in this study would maintain improved 
β cell function and delay the onset of diabetes in prediabetic sub-
jects. Finally, it would be important to know whether mirabegron 
improves glucose homeostasis in individuals with type 2 diabetes.
Methods
Study design and human subjects. This study was intended to examine 
the metabolic effects of mirabegron in obese, insulin-resistant humans 
at the dose approved by the FDA for overactive bladder. Hence, we 
recruited 13 sedentary subjects, aged 35 to 65 years, who had a BMI 
over 27 and either prediabetes, on the basis of HbA1c and a standard 75 
g OGTT, or normal glucose tolerance (NGT) but more than 3 features 
of metabolic syndrome (MetS). Nine of the 13 subjects met at least 1 
criterion for prediabetes at baseline: impaired fasting glucose (100–125 
mg/dL), impaired glucose tolerance (120-minute glucose: 140–199 
mg/dL), or HbA1c of 5.7% to 6.4%. In addition to the OGTT, baseline 
studies were performed in fasted subjects early in the morning in a 
quite, temperature-controlled room (22°C) and included measurement 
of body composition by dual-energy x-ray absorptiometry (DEXA) 
scan and resting metabolic rate (RMR) with a metabolic cart. Other 
baseline studies included a euglycemic clamp, SC WAT and muscle 
(vastus lateralis) biopsies, and PET-CT scans under cold stimulation to 
quantify BAT.
The subjects were recruited from the Lexington, Kentucky, area 
throughout the year, and all subjects had normal thyroid function, no 
chronic inflammatory conditions, and were not taking any medica-
tions, such as beta blockers, steroids, or insulin sensitizers, that would 
interfere with the study. The subjects were asked to continue their 
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50% Ham’s F-10); 3% FBS (Invitrogen, Thermo Fisher Scientific); 
15 mM HEPES, pH 7.4, 33 μM biotin (MilliporeSigma); 17 μM pan-
tothenate (MilliporeSigma); 1 μM dexamethasone (MilliporeSigma); 
0.25 mM 3-isobutyl-1-methylxanthine (IBMX) (MilliporeSigma); 1 × 
10–7 M insulin (Novo Nordisk); and 1 μM rosiglitazone (SmithKline 
Beecham) for 3 days. The cells were then incubated with adipo-
cyte differentiation medium without IBMX and rosiglitazone, with 
medium changes every 3 days until 80%–90% of the cells had lip-
id droplets (7–10 days). Adipocyte CM was prepared by incubating 
differentiated ADHASCs with DMEM with 2% FBS for 24 hours and 
then with DMEM with 2%FBS and 0.1% DMSO (vehicle control) or 
100 nM mirabegron (Cayman Chemical) for 16 hours. CM was also 
isolated and mirabegron added to this medium (100 nM). Adipocyte 
CM was filtered with a 0.2-μm filter and frozen at –80°C for later 
use. Primary myoblasts from human skeletal muscle biopsies from 
healthy subjects were provided by Charlotte Peterson (University of 
Kentucky, Lexington, Kentucky, USA). The myoblasts were differen-
tiated in DMEM with 2% FBS for 10 days. Fully differentiated myo-
tubes were treated with 25 nM mirabegron or 25% adipocyte CM for 
16 hours, and total RNA was prepared for mRNA expression analysis 
using real-time RT-PCR.
NEFA and glycerol measurements in plasma and adipose explant 
secretions. Adipose explant secretions were prepared by incubating 0.5 
grams of the SC WAT biopsy in 2 mL Ringer’s solution supplemented 
with 1% lipid-free BSA at 37°C for 1 hour. Glycerol in the explant secre-
tion was then measured with a High-Sensitivity Free Glycerol Fluo-
rometric Assay Kit (MAK270, MilliporeSigma). Glycerol in plasma 
was measured with Free Glycerol Reagent (F6428, Millipore Sigma). 
NEFAs in plasma or adipose explant secretions were measured with 
HR Series NEFA-HR(2) Color Reagents (999-34691, 995-34791, 991-
34891, 993-35191, FUJIFILM Wako Diagnostics)
Mitochondrial bioenergetics. Bioenergetics of mitochondria puri-
fied from the SC WAT biopsies were determined using an Oxytherm 
System (Hansatech) as previously described (30).
Statistics. A paired Student’s t test or Wilcoxon matched-pairs, 
signed-rank test was performed to compare the results before and 
after mirabegron treatment. Oral glucose tolerance was assessed by 
a repeated-measures 2-way ANOVA with Sidak’s multiple compari-
sons test. Spearman’s correlations were used to assess associations 
between beiging, plasma NEFA levels, and β cell function. Multiple 
comparisons were analyzed by 1-way ANOVA and Tukey’s multiple 
comparisons test. Data were analyzed using GraphPad Prism, version 
8.0 (GraphPad Software). All tests were 2 sided, and statistical signifi-
cance was set at a P value of 0.05 or less.
Study approval. All subjects provided informed consent, and the 
protocols were approved by the IRB of the University of Kentucky.
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rabbit anti-UCP1 (custom antibody J2648, ECM Biosciences). Ampli-
fication was performed with either goat anti–mouse IgG biotin (115-
065-205, Jackson ImmunoResearch) or donkey anti–rabbit IgG biotin 
(711-065-152, Jackson ImmunoResearch) and then streptavidin-HRP 
(S911, Thermo Fisher Scientific), followed by washing and incubation 
with Alexa Fluor Tyramide Reagent (Thermo Fisher Scientific). Sec-
tions were mounted and nuclei stained using VECTASHIELD Anti-
fade Mounting Media with DAPI (H-1800, Vector Laboratories). Mac-
rophages were counted when cells were triple-stained with DAPI and 
CD68, CD86, or CD163. UCP1+CD163+ cells were triple-stained with 
CD163, UCP1, and DAPI. Macrophages were counted within fields of 
adipocytes and not in connective tissue. All data were normalized to 
adipocyte numbers. Images were captured with an upright Zeiss fluo-
rescence microscope.
We performed immunohistochemical analyses on muscle biop-
sies obtained from the vastus lateralis as described previously (73). 
Briefly, frozen muscle sections were cut at 8 μm, air-dried, and stored 
at –20°C. Sections were incubated overnight with isotype-specific 
anti-mouse antibodies against MyHC I IgG2B (BA.D5), MyHC IIa 
IgG1 (SC.71), and MyHC IIx (6H1), obtained from the Developmen-
tal Studies Hybridoma Bank. Sections were then incubated with the 
following secondary antibodies: goat anti–mouse IgG2b Alexa Fluor 
647, anti–mouse IgG1 Alexa Fluor 488, and anti–mouse IgM Alexa Flu-
or 555 (Invitrogen, Thermo Fisher Scientific). The sections were then 
mounted using VECTASHIELD Anti-fade Mounting Media and post-
fixed in methanol. Five to 7 images were captured at ×20 magnifica-
tion using an AxioImager M1 upright fluorescence microscope (Zeiss). 
Fiber type distribution was quantified manually in a blinded manner.
mRNA quantification. Muscle and adipose mRNA was isolated 
using TRIzol extraction and purification with RNeasy Lipid Tissue 
Mini Kits (QIAGEN). The quantity and quality were RNA determined 
using an Agilent 2100 Bioanalyzer. Multiplex analysis of SC WAT 
gene expression was performed using the NanoString nCounter sys-
tem (Nanostring) and a custom code set. The data were normalized to 
the geometric mean of 6 housekeeping genes; the genes and accession 
numbers of the NanoString custom code set are provided in Supple-
mental Table 5. Muscle gene expression was analyzed by real-time 
RT-PCR as described previously (69), and the data were normalized 
to the geometric mean of 6 housekeeping genes (ACTB, PPIA, PPIB, 
TBP, TUBB, and UBC9). The primer sequences are shown in Supple-
mental Table 6.
Quantification of lipids in muscle biopsies. Approximately 10 milli-
grams of the vastus lateralis biopsy was weighed and then extracted 
with acidified organic solvents. DAGs and ceramides were quantified 
as described perviously (74). TGs were quantified in the extract using 
colorimetric TG assays (T7532, Point Scientific). Briefly, lipid extract 
(10 μL) was dried for 5 minutes, and 10 μL 0.1% SDS in 0.9% NaCl 
was added and then incubated for 10 minutes at 37°C. Prewarmed TG 
reagent (1 mL) was added, and the reaction was incubated at 37°C for 
5 minutes. The absorbance (A500) was measured with a Bio-Rad spec-
trophotometer within 30 minutes. Lipid levels were normalized to the 
tissue weight.
Myotube treatment with adipocyte CM. Adult-derived human adi-
pocyte stem cells (ADHASCs) were cultured and differentiated as 
described previously (75). In brief, preadipocytes were incubated for 
48 hours after reaching confluence and induced to differentiate into 
adipocytes with adipocyte differentiation medium (50% DMEM: 
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
2 3 3 0 jci.org   Volume 130   Number 5   May 2020
 1. Arch JR. Challenges in β(3)-adrenoceptor agonist 
drug development. Ther Adv Endocrinol Metab. 
2011;2(2):59–64.
 2. Arch JR. beta(3)-Adrenoceptor agonists: poten-
tial, pitfalls and progress. Eur J Pharmacol. 
2002;440(2-3):99–107.
 3. Arch JR, et al. Treatment of obesity with thermo-
genic beta-adrenoceptor agonists: studies on BRL 
26830A in rodents. Int J Obes. 1984;8 Suppl 1:1–11.
 4. Arch JR, Ainsworth AT. Thermogenic and anti-
obesity activity of a novel beta-adrenoceptor 
agonist (BRL 26830A) in mice and rats. Am J Clin 
Nutr. 1983;38(4):549–558.
 5. Hao L, et al. Beneficial metabolic effects of 
mirabegron in vitro and in high-fat diet-in-
duced obese mice. J Pharmacol Exp Ther. 
2019;369(3):419–427.
 6. Frontini A, Cinti S. Distribution and development 
of brown adipocytes in the murine and human 
adipose organ. Cell Metab. 2010;11(4):253–256.
 7. Wu J, et al. Beige adipocytes are a distinct type of 
thermogenic fat cell in mouse and human. Cell. 
2012;150(2):366–376.
 8. Seale P, et al. Prdm16 determines the thermogen-
ic program of subcutaneous white adipose tissue 
in mice. J Clin Invest. 2011;121(1):96–105.
 9. Cohen P, et al. Ablation of PRDM16 and beige 
adipose causes metabolic dysfunction and 
a subcutaneous to visceral fat switch. Cell. 
2014;156(1-2):304–316.
 10. Min SY, et al. Human ‘brite/beige’ adipocytes 
develop from capillary networks, and their 
implantation improves metabolic homeostasis in 
mice. Nat Med. 2016;22(3):312–318.
 11. Hasegawa Y, et al. Repression of adipose tissue 
fibrosis through a PRDM16-GTF2IRD1 complex 
improves systemic glucose homeostasis. Cell 
Metab. 2018;27(1):180–194.e6.
 12. Chen Y, et al. Thermal stress induces glycolytic 
beige fat formation via a myogenic state. Nature. 
2019;565(7738):180–185.
 13. Cannon B, Nedergaard J. Brown adipose tissue: 
function and physiological significance. Physiol 
Rev. 2004;84(1):277–359.
 14. van Marken Lichtenbelt WD, et al. Cold-activated 
brown adipose tissue in healthy men. N Engl J 
Med. 2009;360(15):1500–1508.
 15. Virtanen KA, et al. Functional brown adi-
pose tissue in healthy adults. N Engl J Med. 
2009;360(15):1518–1525.
 16. Saito M, et al. High incidence of metabolically 
active brown adipose tissue in healthy adult 
humans: effects of cold exposure and adiposity. 
Diabetes. 2009;58(7):1526–1531.
 17. Cypess AM, et al. Identification and importance 
of brown adipose tissue in adult humans. N Engl J 
Med. 2009;360(15):1509–1517.
 18. Klepac K, Georgiadi A, Tschöp M, Herzig S. The 
role of brown and beige adipose tissue in glycae-
mic control. Mol Aspects Med. 2019;68:90–100.
 19. Porter C, Chondronikola M, Sidossis LS. The 
therapeutic potential of brown adipocytes 
in humans. Front Endocrinol (Lausanne). 
2015;6:156.
 20. Kajimura S, Spiegelman BM, Seale P. Brown and 
beige fat: physiological roles beyond Heat Gener-
ation. Cell Metab. 2015;22(4):546–559.
 21. Ikeda K, et al. UCP1-independent signaling involv-
ing SERCA2b-mediated calcium cycling regulates 
beige fat thermogenesis and systemic glucose 
homeostasis. Nat Med. 2017;23(12):1454–1465.
 22. Kazak L, et al. A creatine-driven substrate cycle 
enhances energy expenditure and thermogenesis 
in beige fat. Cell. 2015;163(3):643–655.
 23. Wang W, et al. A PRDM16-driven metabolic sig-
nal from adipocytes regulates precursor cell fate. 
Cell Metab. 2019;30(1):174–189.e5.
 24. Crewe C, An YA, Scherer PE. The ominous triad 
of adipose tissue dysfunction: inflammation, 
fibrosis, and impaired angiogenesis. J Clin Invest. 
2017;127(1):74–82.
 25. Sun K, Kusminski CM, Scherer PE. Adipose 
tissue remodeling and obesity. J Clin Invest. 
2011;121(6):2094–2101.
 26. Sidossis LS, et al. Browning of subcutaneous white 
adipose  tissue in humans after severe adrenergic 
stress. Cell Metab. 2015;22(2):219–227.
 27. Petruzzelli M, et al. A switch from white to brown 
fat increases energy expenditure in cancer-asso-
ciated cachexia. Cell Metab. 2014;20(3):433–447.
 28. Frontini A, et al. White-to-brown transdifferenti-
ation of omental adipocytes in patients affected 
by pheochromocytoma. Biochim Biophys Acta. 
2013;1831(5):950–959.
 29. Kir S, et al. Tumour-derived PTH-related protein 
triggers adipose tissue browning and cancer 
cachexia. Nature. 2014;513(7516):100–104.
 30. Finlin BS, et al. Human adipose beiging in 
response to cold and mirabegron. JCI Insight. 
2018;3(15):121510.
 31. Cypess AM, et al. Activation of human brown adi-
pose tissue by a β3-adrenergic receptor agonist. 
Cell Metab. 2015;21(1):33–38.
 32. Baskin AS, et al. Regulation of human adipose 
tissue activation, gallbladder size, and bile acid 
metabolism by a β3-adrenergic receptor agonist. 
Diabetes. 2018;67(10):2113–2125.
 33. Loh RKC, Formosa MF, La Gerche A, Reutens AT, 
Kingwell BA, Carey AL. Acute metabolic and car-
diovascular effects of mirabegron in healthy indi-
viduals. Diabetes Obes Metab. 2019;21(2):276–284.
 34. Nitti VW, et al. Safety and tolerability of the 
β3-adrenoceptor agonist mirabegron, for the 
treatment of overactive bladder: results of a 
prospective pooled analysis of three 12-week 
randomised phase III trials and of a 1-year 
randomised phase III trial. Int J Clin Pract. 
2014;68(8):972–985.
 35. Pisprasert V, Ingram KH, Lopez-Davila MF, 
Munoz AJ, Garvey WT. Limitations in the use of 
indices using glucose and insulin levels to predict 
insulin sensitivity: impact of race and gender 
and superiority of the indices derived from oral 
glucose tolerance test in African Americans. Dia-
betes Care. 2013;36(4):845–853.
 36. Bergman RN, Finegood DT, Kahn SE. The 
evolution of beta-cell dysfunction and insulin 
resistance in type 2 diabetes. Eur J Clin Invest. 
2002;32 Suppl 3:35–45.
 37. Fan W, Atkins AR, Yu RT, Downes M, Evans RM. 
Road to exercise mimetics: targeting nuclear 
receptors in skeletal muscle. J Mol Endocrinol. 
2013;51(3):T87–T100.
 38. Lin J, et al. Transcriptional co-activator PGC-1 
alpha drives the formation of slow-twitch muscle 
fibres. Nature. 2002;418(6899):797–801.
 39. Mason RR, Watt MJ. Unraveling the roles of 
PLIN5: linking cell biology to physiology. Trends 
Endocrinol Metab. 2015;26(3):144–152.
 40. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, 
Kobilka BK, Isfort RJ. Skeletal muscle hypertro-
phy and anti-atrophy effects of clenbuterol are 
mediated by the beta2-adrenergic receptor. Mus-
cle Nerve. 2002;25(5):729–734.
 41. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, 
Peyot ML, Prentki M. Fatty acid signaling in the 
beta-cell and insulin secretion. Diabetes. 2006;55 
Suppl 2:S16–S23.
 42. Prentki M, Matschinsky FM, Madiraju SR. Meta-
bolic signaling in fuel-induced insulin secretion. 
Cell Metab. 2013;18(2):162–185.
 43. Ježek P, Jabůrek M, Holendová B, Plecitá-Hlavatá 
L. Fatty acid-stimulated insulin secretion vs. lipo-
toxicity. Molecules. 2018;23(6):E1483.
 44. Distel RJ, Robinson GS, Spiegelman BM. Fatty 
acid regulation of gene expression. Transcrip-
tional and post-transcriptional mechanisms.  
J Biol Chem. 1992;267(9):5937–5941.
 45. Heine M, et al. Lipolysis triggers a systemic 
insulin response essential for efficient energy 
replenishment of activated brown adipose tissue 
in mice. Cell Metab. 2018;28(4):644–655.e4.
 46. Magkos F, et al. Effects of moderate and subse-
quent progressive weight loss on metabolic func-
tion and adipose tissue biology in humans with 
obesity. Cell Metab. 2016;23(4):591–601.
 47. Sui W, et al. Bladder drug mirabegron exacer-
bates atherosclerosis through activation of brown 
fat-mediated lipolysis. Proc Natl Acad Sci USA. 
2019;116(22):10937–10942.
 48. Hanssen MJ, et al. Short-term cold acclima-
tion improves insulin sensitivity in patients 
with type 2 diabetes mellitus. Nat Med. 
2015;21(8):863–865.
 49. van der Lans AA, et al. Cold acclimation recruits 
human brown fat and increases nonshivering ther-
mogenesis. J Clin Invest. 2013;123(8):3395–3403.
 50. Yoneshiro T, et al. Recruited brown adipose tissue 
as an antiobesity agent in humans. J Clin Invest. 
2013;123(8):3404–3408.
 51. Hanssen MJ, et al. Short-term cold acclimation 
recruits brown adipose tissue in obese humans. 
Diabetes. 2016;65(5):1179–1189.
Address correspondence to: Philip A. Kern, Division of Endocri-
nology, CTW 521, University of Kentucky, 900 South Limestone 
Street, Lexington, Kentucky 40536, USA. Phone: 859.218.1394; 
philipkern@uky.edu.
edge Charlotte Peterson for providing the primary myoblasts and 
Rachel Davidowitz for her help with the graphical abstract. This 
study was funded by NIH grants DK112282, P30GM127211, and 
DK 71349 and by CTSA, NIH grant UL1TR001998.
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
2 3 3 1jci.org   Volume 130   Number 5   May 2020
 52. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Schrau-
wen P, van Marken Lichtenbelt WD. Brown 
adipose tissue in morbidly obese subjects. PLoS 
ONE. 2011;6(2):e17247.
 53. Chondronikola M, et al. Brown adipose tissue 
activation is linked to distinct systemic effects 
on lipid metabolism in humans. Cell Metab. 
2016;23(6):1200–1206.
 54. Fischer AW, et al. UCP1 inhibition in Cidea-over-
expressing mice is physiologically counteracted 
by brown adipose tissue hyperrecruitment. Am J 
Physiol Endocrinol Metab. 2017;312(1):E72–E87.
 55. Chouchani ET, et al. Mitochondrial ROS regulate 
thermogenic energy expenditure and sulfenyla-
tion of UCP1. Nature. 2016;532(7597):112–116.
 56. Fisher FM, Maratos-Flier E. Understanding 
the physiology of FGF21. Annu Rev Physiol. 
2016;78:223–241.
 57. Schwartz DR, Lazar MA. Human resistin: found 
in translation from mouse to man. Trends Endo-
crinol Metab. 2011;22(7):259–265.
 58. Chen BH, et al. Circulating levels of resistin and 
risk of type 2 diabetes in men and women: results 
from two prospective cohorts. Diabetes Care. 
2009;32(2):329–334.
 59. Heidemann C, et al. Total and high-molecu-
lar-weight adiponectin and resistin in relation to 
the risk for type 2 diabetes in women. Ann Intern 
Med. 2008;149(5):307–316.
 60. Kern PA, Simsolo RB, Fournier M. Effect of 
weight loss on muscle fiber type, fiber size, 
capillarity, and succinate dehydrogenase 
activity in humans. J Clin Endocrinol Metab. 
1999;84(11):4185–4190.
 61. Wilson JM, Loenneke JP, Jo E, Wilson GJ, Zourdos 
MC, Kim JS. The effects of endurance, strength, 
and power training on muscle fiber type shifting. 
J Strength Cond Res. 2012;26(6):1724–1729.
 62. Ryall JG, Lynch GS. The potential and the pitfalls 
of beta-adrenoceptor agonists for the manage-
ment of skeletal muscle wasting. Pharmacol Ther. 
2008;120(3):219–232.
 63. Ohnuki Y, et al. Role of masseter muscle β2-ad-
renergic signaling in regulation of muscle activi-
ty, myosin heavy chain transition, and hypertro-
phy. J Pharmacol Sci. 2013;123(1):36–46.
 64. Lo JC, et al. Adipsin is an adipokine that improves 
β cell function in diabetes. Cell. 2014;158(1):41–53.
 65. Stern JH, Rutkowski JM, Scherer PE. Adiponec-
tin, leptin, and fatty acids in the maintenance of 
metabolic homeostasis through adipose tissue 
crosstalk. Cell Metab. 2016;23(5):770–784.
 66. Holland WL, et al. Receptor-mediated activation of 
ceramidase activity initiates the pleiotropic actions 
of adiponectin. Nat Med. 2011;17(1):55–63.
 67. Sun K, Tordjman J, Clément K, Scherer PE. Fibro-
sis and adipose tissue dysfunction. Cell Metab. 
2013;18(4):470–477.
 68. Kosteli A, et al. Weight loss and lipolysis promote 
a dynamic immune response in murine adipose 
tissue. J Clin Invest. 2010;120(10):3466–3479.
 69. Finlin BS, et al. Mast cells promote seasonal 
white adipose beiging in humans. Diabetes. 
2017;66(5):1237–1246.
 70. Walton RG, et al. Human skeletal muscle macro-
phages increase following cycle training and are 
associated with adaptations that may facilitate 
growth. Sci Rep. 2019;9(1):969.
 71. Finlin BS, et al. Effect of rifaximin treatment on 
endotoxemia and insulin sensitivity in humans.  
J Endocr Soc. 2019;3(9):1641–1651.
 72. Chen KY, et al. Brown adipose reporting criteria 
in imaging studies (BARCIST 1.0): recommenda-
tions for standardized FDG-PET/CT experiments 
in humans. Cell Metab. 2016;24(2):210–222.
 73. Murach KA, et al. Depletion of Pax7+ satellite 
cells does not affect diaphragm adaptations 
to running in young or aged mice. J Physiol. 
2017;595(19):6299–6311.
 74. Walton RG, et al. Increasing adipocyte lipo-
protein lipase improves glucose metabolism 
in high fat diet-induced obesity. J Biol Chem. 
2015;290(18):11547–11556.
 75. Rasouli N, et al. Association of scavenger recep-
tors in adipose tissue with insulin resistance in 
nondiabetic humans. Arterioscler Thromb Vasc 
Biol. 2009;29(9):1328–1335.
